Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Contemp Clin Trials. 2017 Dec 5;65:33–38. doi: 10.1016/j.cct.2017.11.014

Table 1.

Inclusion and exclusion criteria for Step 1 and Step 2

Step 1 Step 2
Inclusion criteria Ages 1 month to 18 years As in Step 1
Diagnosis of Kawasaki disease: 5 days of fever and 4 out of 5 symptoms (conjunctival injection, palmar or solar edema, cervical lymphadenopathy, lingual or labial erythema, maculopapular rash)
Diagnosis and hospitalization within 3 weeks of fever onset
Informed consent (and assent)
Coronary artery dilation with a z-score ≥ 2.5
Exclusion criteria Denial of consent/assent As in Step 1
Fever onset more than 3 weeks prior to diagnosis and hospitalization
Tetracycline or sulfite allergy or prior treatment with tetracyclines (< 8 years of age)
Kidney failure (creatinine level above the upper limit of normal for age)
Liver failure (AST, ALT, bilirubin or GGT level elevated 5x above the upper limit of normal for age)